---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038008"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T05:57:19.296177+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use

## Summary
- Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).
- Cash and equivalents $51.1M as of Dec 31, 2023; down from $56.4M year-end 2022.
- 12 participants enrolled in Phase 2 BESTOW trial of tegoprubart vs tacrolimus in kidney transplant.
- Phase 1b data (n=11) showed tegoprubart safe, with eGFR >70 mL/min at all post-90-day time points.
- Tegoprubart used in first pig-to-human kidney xenotransplant on March 16, 2024 at Massachusetts General Hospital.

## SEC filing metadata
- accession: 0000950170-24-038008
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/eldn-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038008
- JSON: https://secwatch.observer/filing/0000950170-24-038008.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038008.txt

## Key facts
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.
  - Period: the year ended December 31, 2023
  - Net income: net loss of $40.3 million, or $1.64 per share
  - EPS: $1.64 per share
  - Result: reported results
  source text: The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm
- Earnings Releases
  Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.
  - Period: the three months ended December 31, 2023
  - Net income: net loss of $9.6 million, or $0.32 per share
  - EPS: $0.32 per share
  - Result: reported results
  source text: The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.